Apyx Medical (NASDAQ:APYX) announced its quarterly earnings results on Tuesday. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07, MarketWatch Earnings reports. Apyx Medical had a negative return on equity of 24.21% and a negative net margin of 64.16%.
Shares of APYX stock traded up $0.10 during trading hours on Thursday, hitting $9.76. 150,652 shares of the company’s stock were exchanged, compared to its average volume of 95,671. The stock’s 50-day moving average is $10.53 and its 200-day moving average is $7.95. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.05 and a quick ratio of 6.49. The stock has a market cap of $334.52 million, a price-to-earnings ratio of -20.77 and a beta of 0.72. Apyx Medical has a 52 week low of $2.81 and a 52 week high of $12.01.
A number of analysts have weighed in on APYX shares. Colliers Securities reiterated a “buy” rating on shares of Apyx Medical in a research report on Tuesday. Zacks Investment Research cut Apyx Medical from a “buy” rating to a “hold” rating in a research report on Tuesday, March 16th. Finally, Piper Sandler upped their price target on Apyx Medical from $8.00 to $12.00 and gave the company an “overweight” rating in a research report on Friday, January 29th.
Apyx Medical Corporation, a energy technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. It operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). The company develops J-Plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue.
Featured Article: How can you know how many shares are floating?
Receive News & Ratings for Apyx Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apyx Medical and related companies with MarketBeat.com's FREE daily email newsletter.